Сравнительная эффективность длительного применения антагонистов АТ1 рецепторов к ангиотензину II и \Nb-блокатора у пациентов с тяжелой ХСН с непереносимостью иАПФ
Диссертация
Краеугольным камнем" в лечении ХСН названы и все еще остаются ингибиторы ангиотензин-превращающего фермента (иАПФ), которые входят в стандартную схему терапии ХСН. Но, к сожалению, существует ряд причин, при которых эти препараты не эффективны или применять их нельзя. Блокада образования ангиотензина II с помощью иАПФ не затрагивает не АПФ-зависимых путей (химазы и др.) и является неполной. Кроме… Читать ещё >
Список литературы
- Арутюнов Г. П., Вершинин А. А., Рылова А. К. Опыт длительного применения Эналаприла, Лозартана и их комбинации у больных с недостаточностью кровообращения в постинфарктном периоде.//Кардиология. 2000- 4:46−51.
- Арутюнов Г. П., Рылова А. К. Роль блокады альдостерона в комплексной терапии сердечной недостаточности. //Тер. Архив. 1999- 12: 72−74.
- Багров Я.Ю. Водно-солевой гомеостаз при недостаточности кровообращения. -Л.:Наука, 1984−176с.
- Вандер А. Физиология почек: Пер. с англ. СПб. Питер, 2000−156с
- Визир В. А. Березин А.Е. Лозартан в теарпии хронической сердечной недостаточности. // Клиническая медицина -2000- 2:36−39.
- Гиляревский С.Р., Орлов В. А. Терапевтическая тактика при возникновении побочных эффектов ингибиторов АПФ. // Клин, фармакол. тер. 1997- 4:74−80.
- Кржыжановский В.А. Диагностика и лечение сердечной недостаточности. «Знание—М» Москва, 1998- 182с.
- Кутырина И. М. Шестакова М.В. Антогонисты рецепторов ангиотензина II новый этап в тактике нефропротекции при диабетической нефропатии.СопБШит Medicum. 2003−5(9):7−11.
- Маколкин В. И. Подзолков В.И. Гипертоническая болезнь, М., 2000 г.
- Метелица В.И. Блокаторы рецепторов ангиотензина II. Лекция.//Тер. архив.-1996- 8:64−67.
- Мухин Н.А. Современная нефропротективная стратегия лечения хронических прогрессирующих заболеваний почек // Клин, фармакол. тер. 2001- 11:58−62.
- Подзолков В.И., Самойленко В. В., Булатов В. А. Антигипертензиврая -терапия и концепция нефропротекции // Сердце. 2003- 1: 128−3 h
- Преображенский Д.В., Сидоренко Б. А., Сопалева Ю. В., Иосава И. К. Физиология и фармакология ренин-ангиотензиновой системы // Кардш^гая.-1997−11:91−95.
- Преображенский Д. В. Сидоренко Б.А. Результаты клинического исследования CALM.Consilium-Medicum. 2001−3(10):12−17.
- Скворцов Б. А. Мареев В.Ю.Беленков Ю. Н. Блокаторы рецепторов ангиотензина II (механизмы дествия, первые клинические результаты) // Кардиология .-1998−4:36−50.
- Сторожаков Г. И. Бета-блокаторы в лечении хронической сердечной недостаточности //Сердечная недостаточность. 2001 -2(1): 27−28.
- Тэйлор Дж. Дж. «Основы кардиологии». Пер. с англ.— «МЕДпресс—информ». Москва.2004−366с.
- Швецов М.Ю., Медведева Т. Ю., Оконова Е. Б. и др Блокаторы ангиотензиновых рецепторов 1 типа новый класс нефропротективных препаратов // Клиническая фармакология и терапия. 2001 -11: 62−64.
- Akishita М, Iwai М, Wu L, et al. Inhibitory effect of angiotensin II type 2 receptor on coronary arterial remodeling after aortic banding in mice. Circulation 2000- 102:1684−9.
- Aldigier JC, Huang H, Dalmay F, et al. Angiotensin-converting enzyme inhibition does not suppress plasma angiotensin II increase during exercise in humans. J Cardiovasc Pharmacol 1993- 21:289−95.
- Anker S.D., Coats A.J.S., Roccker E.B. et al. Does carvedilol prevent and reverse cardia cachexia in patients with severe heart failure? Results of the COPERNICUS study // Europ. Heart J. 2002−4 (Suppl. Abstr.):394.
- Barr CS, Lang CC, Hanson J, et al. Effects of adding spironolactone to an angiotensin-convertmg enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995- 76:1259−65.
- Borghi C, Boschi S, Ambrosioni E, Melandri G, Branzi A, Magnani I. Evidence of a partial escape of renin- angiotensin -aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol 1993−33:40−5.
- Bottorff MB, Tenero DM. Pharmacokinetics of eprosartan in healthy subjects, patients with hypertension, and special populations. Pharmacotherapy 1999:19(4 pt2):73S-8.
- Bourne M, Meunier V, Bcrger Y, Fabre G. Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes. Drug Mctab Dispos 1999- 27:288−96.
- Braunwald E. Grossman W: Clinical aspects of heart failure. In Braunwald E. (ed): Heart Disease. A Textbook of Cardiovascular Medicinc -4th edition. W.B.Saunders Co, Philadelfia, 1992.
- Brenner BM, Cooper ME, de Zeeuw D, et al, for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001:345:861−9.
- Brilla CG, Weber KT: Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 1992−120:893−901.
- Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin П and aldosterone. J Mol Cell Cardiol 1994- 26:809−20.
- Brilla DG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 1990- 67:1355−64.
- Brunner -La Rossa H, Vaddadi G, Esler MD. Resent insight into therapy of congestive heart failure: Focus on ACE inhibitor and angiotensin-II antagonism. J Am Coll Cardiol 1999- 33:1163−73.
- Burnier M, Brunner HR. Renal effects of angiotensin II receptor blockade and angiotensin-converting enzyme inhibition in healthy subjects. Exp Nephrol 1996- 4(suppl l):41−6.
- Burnier M, Hagmann M, Nussberger J, et al. Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects. Hypertension 1995:25:602−9.
- Burnier M, Rutschmann B, Nussberger J, et al. Salt-dependent renal ef an angiotensin II antagonist in healthy subjects. Hypertension 1993- 22:339−47.
- CIBIS-II Investigators and Commitees. The Cardiac Insuffiency Bisoprolol Study II (CIBIS-II): a randomised trial // Lancet. 1999−353:9−13.
- Cleland JG, Dargie HJ, Hodsman GP, et al. Captopril in heart failure: a double blind controlled trial. Br Heart J. 1984- 52:5305.
- Conn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001:345:1667−75.
- Crozier I, Ikram H, Awan N, et al. Losartan in heart failure: hemodynamic effects and tolerability. Circulation 1995- 91:691−7.
- Csajka C, Buclin T, Brunner HR, Biollaz J. Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists. Clin Pharmacokinet 1997−32:1−29.
- Csikos T, Chung O, Unger T. Receptors and their classification: focus on angiotensin II and the AT2 receptor. J Hum Hypertens 1998- 12:311−18.
- Dahlof B, Devcreux RB, Kjeldsen SE, et al, for the LIFE Study Group. Cardiovascular morbidity and mortality in the losartan intervention forendpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002:359:995−1003.
- De Gasparo M, Levens N. Does blockade of angiotensin II receptors offer clinical benefits over inhibition of angiotensin-converting enzyme? Pharmacol Toxicol 1998- 82:257−71.
- Dickstein K, Chang P, Willenheimer R, et al. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol 1995−26:438−45.
- Dunn FG, Oigman W, Ventura HO, Messerli FH, Kobrin I, Frohlich ED. Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension. Am J Cardiol 1984−53:105−8.
- Duprez DA, Dc Buyzere ML, Rietzschel ER, et al. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J 1998- 19:1371−6.
- Farquharson CA, Struthers AD. Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-in-duced vasculopathy. Clin Sci (Lond) 2002- 103:425−30.
- Fogari R, Zoppi A, Corradi L, Lazzari P, Mugellini A, Lusardi P. Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of nondiabetic hypertensive patients. Br J Clin Pharmacol 1998:46:467−71.
- Francis GS, Goldsmith SR, Levine B, Olivari MT, Cohn JN. The neurohormonal axis in congestive heart failure .Ann Intern Med 1984- 101:3707.
- Frierdich G, Schuh J, Brown M, Nochowiak D, Blehm D, Delyani JA. Effects of the selective mineralocorticoid receptor antagonist, epler-enone, in a model of aldosterone-induced hypertension and cardiac fibrosis. Am J Hypertens 1998- 11:94A.
- Frye CB, Pettigrew TJ. Angioedema and photosensitive rash induced by valsartan. Pharmacotherapy 1998−18:866−8.
- Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995:273:1450−6.
- Gillis JC, Markham A. Irbesartan: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs 1997:54:885−902.
- Gottlieb SS, Baruch L, Kukin ML, Bernstein JL, Misher ML, Packer M. Prognostic importance of the serum magnesium concentration in patients with congestive heart failure. J Am Coll Cardiol 1990- 16:827−31
- Guazzi M, Palermo P, Pontone G, Susini F, Agostoni P. Synergistic efficacy of enalapril and losartan on exercise performance and oxygen consumption at peak exercise in congestive heart failure. Am J Cardiol 1999:84:1038−43.
- Hamroff G, Katz SD, Mancini D, et al. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation 1999- 99:990−2.
- Havranek WP, Thomas I, Smith WB, et al. Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure. J Am Coll Cardiol 1999:33:1174−81.
- Heart Failure Society of America. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction: pharmacological approaches. Pharmacotherapy 2000- 20:495−522.
- Hebert LA, Falkenhain ME, Nahman NS Jr, Cosio FG, O’Dorisio TM. Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy. Am J Nephrol 1999- 19:1−6.
- Heitzer T, Schlinzig T, Krohn K, et al. Endothelial dysfunction, oxidative stress and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001- 104:2673−8.
- Horiuchi M, Akishita M, Dzau VJ. Recent progress in angiotensin type 2 receptor research in the cardiovascular system. Hypertension 1999- 33:613−21.
- Ikeda U, Kanbe T, Nakayama I, Kawahara Y, Yokoyama M, Shi-mada K. Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induce by interleukin-lB. Eur J Pharmacol 1995- 290:69−73.
- Jong P, Demers C, McKelvie RS, Liu PP. Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. J Am Coll Cardiol 2002 -39:463−70.
- Julius S. Long-term potential of angiotensin receptor blockade for cardiovascular protection in hypertension: the VALUE trial. Cardiology 1999−91(suppl 1):8−13.
- Kaukonen KM, Olkkola KT, Neuvonen PJ. Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. Eur J Clin Pharmacol 1998:53:445−9.
- Kim S, Zhan Y, Izumi Y, Iwao H. Cardiovascular effects of combination of perindopril, candesartan, and amlodipine in hypertensive rats. Circulation 2000- 35:769−74.
- Kjeldsen SE, Julius S, Brunner H, et al, for the VALUE Trial Group. Characteristics of 15,314 hypertensive patients at high coronary risk: the VALUE trial. Blood Pressure 2001- 10:1−11.
- Krum H., Roecker F.B., Monacsi P. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. JAMA. 2003−289:712−718.
- Lee AF, MacFadyen RJ, Struthers AD. Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study. Eur J Heart Fail 1999- 401 -6.
- Lewis J, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993- 329:1456−62.
- Lewis J, Hunsicker LG, Clarke WR, et al, for the Collaborative Study Group. Renoprotective effect of the angiotcnsin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001- 345:851−60.
- Liu YH, Yang XP, Sharov VG, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type-1 receptor antagonists in rats with heart failure: role of kinins and angiotensin II type 2 receptors. J Clin Invest 1997:99:1926−35.
- Luzier AB, Forrest A, Adelman M, Hawaii Fl, Schentag JJ, Izzo JL Jr. Impact of angiotensin-converting enzyme inhibitor underdosing on rehospitalization rates in congestive heart failure. Am J Cardiol 1998- 82:465−9.
- MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces morning rise in heart rate in heart failure patients. Cardiovasc Res 1997- 35:30−4.
- MacFadyen RJ, Lee AF, Morton JJ, Pringle SD, Struthers AD. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart 1999- 82:57−61.
- Maggioni AP, Anand I, Gottlieb SO, Latini R, Tognoni G, Cohn JN. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2002−40:1414−21.
- Mann J, Julius S, for the VALUE Trial Group. The valsartan antihypertensive long-term use evaluation (VALUE) trial of cardiovascular events in hypertension: rationale and design. Blood Pressure 1998−7:176−83.
- Markham A, Goa KL. Valsartan: a review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997−54:299−311.
- McClellan KJ, Goa KL. Candesartan cilexetil: a review of its use in essential hypertension. Drugs 1998:56:847−69.
- McClellan KJ, Markham A. Telmisartan. Drugs 1998−56: 1039−44.
- McCune SA, Carraway JW, Radin MJ, Holycross BJ. Comparison of irbesartan to captopril in heart failure prone male SHHF/MCCFAcp rats abstr. J Hypertens 1996- 14(suppl):S137.
- Meffert S, Stol M, Steckelings UM, Bottari SP, Unger T. The angiotensin II AT2 receptor inhibits proliferation and promotes differentiation in PC12W cells. Mol Cell Endocrinol 1996- 122:59−67.
- Merck & Co., Inc. Cozaar (losartan potassium) product information. Whitehouse Station, NJ- 2001.
- Messerli FH, Weber MA, Brunner HR. Angiotensin II receptor inhibition: a new therapeutic principle. Arch Intern Med 1996:156:1957−65.
- Milavetz JJ, Raya ТЕ, Morkin E, Goldman S. Survival after large myocardial infarction in rats: comparison of ACE inhibition with captopril versus direct angiotensin II blockade with losartan. J Am Coll Cardiol 1996:27:714−19.
- Mimran A, Ribstein J. Angiotensin receptor blockers: pharmacology and clinical significance. J Am Soc Nephrol 1999−10:S273−7.
- Moan A, Hoieggen A, Nordby G, Eide IK, Kjeldsen SE. Effects of losartan on insulin sensitivity in severe hypertension: connections through sympathetic nervous system activity? J Hum Hypertens 1995−9(suppl 5):S45−50.
- Modena MG, Aveta P, Menozzi A, Rossi R. Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction. Am J Heart 2001−141:41−6.
- Morgan T. Effect of combining angiotensin receptor blockers and ACE inhibitors on cardiovascular disease. J Renin-Angiotensin-Aldosterone Sys 2001−2(suppl l):S223−36.
- Muirhead N, Feagan BF, Mahon J, et al. The effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellitus: a placebo-controlled trial. CurrTher Res 1999−60:650−60.
- Murdoch DR, McDonagh ТА, Farmer R, Morton JJ, McMurray JJV, Dargie HJ. ADEPT: Addition of the ATI receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects. Am Heart J 2001−141:800−7.
- Nakagawa H, Daihara M, Tamakawa H, Nozue T, Kawahara K. Effects of quinapril and losartan on insulin sensitivity in genetic hypertensive rats with different metabolic abnormalities. J Cardiovasc Pharmacol 1999−34:28−33.
- Nakashima Y, Fouad FM, Tarazi RC. Regression of left ventricular hypertrophy from systemic hypertension by enalapril. Am J Cardiol 1984−53:1044−9.
- Obayashi M, Yano M, Kohno M, et al. Dose-dependent effect of ANG 11-receptor antagonist on myocyte remodeling in rat cardiac hypertrophy. Am J Physiol 1997−273(4 pt 2):H1824−31
- CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987−316:1429−35.
- Packer M. Assessment of treatment with lisinopril and survival (ATLAS). J Am Coll Cardiol 1998−32:1−7.
- Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992−20:248−54.
- Patterson JH, Adams KF. Pathophysiology of heart failure. Pharmacotherapy 1993- 13(5 pt2):73S-81.
- Pfeffer MA, McMurray J, Leizorovicz A, et al, for the VALIANT Investigators. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. Am Heart J 2000- 140:727−34.
- Philbin EF, Andreaou C, Rocco ТА, Lynch LJ, Baker SL Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitals. Am J Cardiol 1996−77:832−8.
- Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003−348:1309−21.
- Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (evaluation of losartan in the elderly study, ELITE). Lancet 1997−349:747−52.
- Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999:341:709−17.
- Pontremoli R., Nicolella C., Viazzi F. et al. Microalbuminuria is an early marker of target organ damage in essential hypertension. Amer J Hypertens., 1998-l l (4):430−438.
- PS Sato A, Suzuki Y, Saruta T. Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension. Hypertens Res 1999−22:17−22.
- Rajogopalan S, Duquaine D, King S, Pitt B, Patel P. Mineralocorti-coid receptor antagonism in experimental atherosclerosis. Circulation 2002−105:2212−6.
- Riegger GAJ, Bouzo H, Petr P, et al. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Circulation 1999- 100:2224−30.
- Rocha R, Rudolph AE, Frierdich GE, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002−283:H 1802−10.
- Rockman HA, Wachorst SP, Mao L, Ross J Jr. ANG II receptor blockade prevents ventricular hypertrophy and ANF gene expression with pressure overload in mice. Am J Physiol 1994−226(6 pt 2):H2468−75.
- Roig E, Perez-Villa F, Morales M, et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J 2002−21:53−7.
- Rossi GP, DiBello V, Ganzaroli C, et al. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension 2002−40:23−7.
- Rouleau J.L., Krum H., Katus H.A. Effisacy and safety of carvedilol in patients with low systolic blood pressure in theCOPERNICUS study // Europ. Heart J. 2002−4(Suppl. Abstr.)-396.
- Rouleau JL. The neurohormonal hypothesis and the treatment of heart failure. Can J Cardiol 1996- 12 (suppl F):3F-8.
- Rutherford JD, Pfeffer MA, Moye LA, et al, for the SAVE Investigators. Effects of captopril on ischemic events after myocardialinfarction: results of the survival and ventricular enlargement trial. Circulation 1994−90:1731−8.
- Sato A, Saruta T. Aldosterone escape during angiotensin-convertmg enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 2001−29:13−21.
- Sica Domenic A. Angiotenzin-Converting Enzyme Inhibitors Side Effects—Physiologic and Non -Physiologic Considerations J Clin.Hypertens. 2004−6(7):410−416.
- Siragy HM, de Gasparo M, EI-Kersh M, Carey RM. Angiotensin-converting enzyme inhibition potentiates angiotensin II type 1 receptor effects on renal bradykinin and cGMP. Hypertension 2001−38:183−6
- Sleight P. Angiotensin II and trials of cardiovascular outcomes. Am J Cardiol 2002−89(suppl 2A):11 A-16.
- SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991−325:293−302.
- Stafford RS, Saglam D, Blumenthal D. National patterns of angiotensin-converting enzyme use in congestive heart failure. Arch Intern Med 1997- 157:2460−4.
- Suzuki G, Morita H, Mishima T, et al. Long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 2002−106:2967−72.
- Svvedbcrg К, Encroth P, Kjedhus J, et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990−82:1730−6.
- Swedberg K, Pfeffer M, Granger C, et al, for the CHARM-Programme Investigators. Candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM): rationale and design. J Card Fail 1999:5:276−82.
- The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the cooperative north Scandinavian enalapril survival study. N Engl J Med 1987−316:1429−35.
- The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000−355:253−9.
- The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000−342:145−53.
- The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992−327:685−91.
- The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991−325:293−302.
- Tsuji H, Venditti Jr FJ, Evan JC et al. The association of levels of serum potassium and magnesium with ventricular premature complexes (the Framingham Heart Study). Am J Cardiol 1994−74:232−5.
- Urata H, Helaey B, Stewart RW, Bumpus FM, Husain A. Angiotensin 11-forming pathways in normal and failing human hearts. Circ Res 1990−66:883−90.
- Urata H, Boehm KD, Philip A, et al. Cellular localization and regional distribution of angiotensin 11-forming chymase in the heart. J Clin Invest 1993−91:1269−81.
- Vacher E, Fornes P, Richer C, Bruneval P, Nisato D, Giudicelli JF. Early and late haemodynamic and morphological effects of angiotensin II subtype 1 receptor blockade during genetic hypertension development. J Hypertens 1995- 14:675−82
- Vantrimpont P, Rouleau JL, Ciampi A, et al. Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study. Eur Heart J 1998−19:1552−63.
- Wang W, McClaim JM, Zucker Ш. Aldosterone reduces baroreceptor discharge in the dog. Hypertension 1992−19:270−7.
- Wang W. Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. Hypertension 1994−24:571−5.
- Weber KT. A neuroendocrine-immune interface. The immunostimu-latory state of aldosteronism. Herz 2003−28:692−701.
- Willenheimer R, Dahlb’f B, Rydberg E et al. ATI-receptor blockers in hypertension and heart failure: clinical experience and future directions. Eur Heart J. 1999−20(14):997−1008
- Williamson KM, Patterson JH, McQueen RH, Adams KF Jr, Pieper JA. Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 1998−63:316−23.
- Woo J., Cockram C.S., Swammathan R. et al. Microalbuminuria and other cardiovascular risk eactors in nondiabetic subjects. Int.J.Cardiol., 1992−37:345−350.
- Yee KM, Struthers AD. Aldosterone blunts the baroreflex response in man. Clin Sci 1998−95:687−92.
- Yoshiyama M, Kim S, Yamagishi H, et al. Cardioprotective effect of the angiotensin II type 1 receptor antagonist TCV-116 on ischemia-reperfusion injury. Am Heart J 1994- 128:1−6.
- Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992−340:1173−8.
- Zannad F, Alia F, Dousett B, Perez A, Pitt B. Limitation of excessive matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure. Circulation 2000- 102:2700−6.